Early-stage bilayer tissue-engineered skin substitute formed by adult skin progenitor cells produces an improved skin structure in vivo

Qun Zhang, Jie Wen, Chang Liu, Chuan Ma, Fuxiang Bai, Xue Leng, Zhihong Chen, Zhiwei Xie, Jun Mi and Xunwei Wu

Abstract

**Background:** In recent years, significant progress has been made in developing highly complex tissue-engineered skin substitutes (TESSs) for wound healing. However, the lack of skin appendages, such as hair follicles and sweat glands, and the time required, are two major limitations that hinder its broad application in the clinic. Therefore, it is necessary to develop a competent TESS in a short time to meet the needs for clinical applications.

**Methods:** Adult scalp dermal progenitor cells and epidermal stem cells together with type I collagen as a scaffold material were used to reconstitute bilayer TESSs in vitro. TESSs at 4 different culture times (5, 9, 14, and 21 days) were collected and then grafted onto full-thickness wounds created in the dorsal skin of athymic nude/nude mice. The skin specimens formed from grafted TESSs were collected 4 and 8 weeks later and then evaluated for their structure, cell organization, differentiation status, vascularization, and formation of appendages by histological analysis, immunohistochemistry, and immunofluorescent staining.

**Results:** Early-stage bilayer TESSs after transplantation had a better efficiency of grafting. A normal structure of stratified epidermis containing multiple differentiated layers of keratinocytes was formed in all grafts from both early-stage and late-stage TESSs, but higher levels of the proliferation marker Ki-67 and the epidermal progenitor marker p63 were found in the epidermis formed from early-stage TESSs. Interestingly, the transplantation of early-stage TESSs produced a thicker dermis that contained more vimentin- and CD31-positive cells, and importantly, hair follicle formation was only observed in the skin grafted from early-stage TESSs. Finally, early-stage TESSs expressed high levels of p63 but had low expression levels of genes involved in the activation of the apoptotic pathway compared to the late-stage TESSs in vitro.

(Continued on next page)
Background
Skin injuries from accidents, diseases, chronic wounds, acute trauma, burns, etc. can compromise the skin barrier and potentially lead to permanent disability or death of the injured person depending on the severity of the wound. According to the latest statistics, 450,000 burn injuries require medical attention annually in the USA, and 40,000 of those patients require hospitalization and the cost is significant [1]. Skin grafting is one of the most promising approaches to heal extensive wounds [2], and without grafts, full-thickness skin wounds with diameters larger than 4 cm are difficult to heal [3]. However, autografts are not always available, particularly for burn patients. In only very limited numbers of cases, patients have suitable autografts for transplantation. For allografts, the demand for skin tissues seriously exceeds the supply, and moreover, foreign tissues have the additional problem of potential immune rejection. Since tissue engineering was formally introduced in the late 1980s, tissue-engineered skin substitutes (TESSs) have become an attractive solution to treat acute and chronic cutaneous wounds [4, 5]. The common method used to create TESSs involves seeding a biodegradable scaffold with cells including epidermal keratinocytes, dermal fibroblasts, and/or stem cells. In recent decades, human TESSs have evolved from simple epidermal substitutes to complex full-thickness skins with a bilayer containing both epidermal and dermal layers that are also commercially available for clinical applications [6–9]. However, there is still much room for improvement given the many practical and therapeutic limitations of TESSs at this time [6].

On one hand, the complete regeneration of perfect skin with full functions (protection, regulation, and sensation) is still challenging and has become a major aim in wound healing [10]. Although current TESSs have been improved by the implementation of various appendages, including a capillary network [11], sensory innervation [12], adipose tissue [13], and pigment production [14], it remains impossible to reliably reconstitute full skin functions, most notably functional hair follicles and sweat glands [15]. The failure of cultured cells to regenerate hair follicles has been ascribed to the loss of trichogenicity during expansion in culture [16–18]. Therefore, it is crucial for effective regenerative medicine to develop an optimal system to maintain cell regeneration potential in vitro. The availability of adult stem cells and induced pluripotent stem cells (iPSCs) from patients provides opportunities to eventually generate those structures without the risk of immune rejection [19, 20]. On the other hand, since extensive cell culture procedures are involved in producing the different cell types used, the reconstruction of full-thickness TESSs is very time-consuming. Cells required for epidermal and dermal components of bilayer TESSs usually require 2 to 4 weeks of culture to obtain sufficient numbers of cells to produce TESSs, which then need another 3 or more weeks of culture before they are ready for grafting, which is a major constraint for their regular use as an autologous product for treating wounds in the clinic. Therefore, shortening the culture time required both for cell expansion and for reconstitution of TESSs would have a significant benefit for the clinical application of autologous TESSs.

Recently, we established a simple and quick method to efficiently isolate human skin epidermal and dermal stem cells [21] and to shorten the initial culture time required for the expansion of those skin progenitor cells [22]. Importantly, these human skin cells after expansion in our system still maintain their potential to generate full-thickness skin with hair follicles [23]. Here, we used our method to prepare skin progenitor cells to reconstitute bilayer TESSs and explored whether early-stage TESSs with a short culture time were able to form skin structures similar to late-stage TESSs in vivo after transplantation (Additional file 1: Figure S1).

Materials and methods
Preparation of skin progenitor cells
Skin progenitor cell preparations followed the procedures described in our previous publications [21, 22, 24]. Human epidermal stem cells and human dermal progenitor cells were derived from adult scalp tissues (males, age 20–30 years old). The adult scalp tissues were collected from discarded hospital specimens following methods approved by the Medical Ethical Committee of the School of Stomatology, Shandong University (No. 2015120401; date: 05 December 2015), without any personal identity information. The epidermal stem cells were cultured in K-SFM (Cat. 10725-018, Thermo Fisher Scientific, Waltham, MA, USA) plus...
5 μM Y-27632 (Cat. Y0503, Sigma-Aldrich, St. Louis, MO, USA), and the medium was changed every other day. The dermal progenitor cells were cultured in DMEM (Cat. 12430054, Thermo Fisher Scientific)/F12 (Cat. 21127022, Thermo Fisher Scientific) (3:1) containing 5% fetal bovine serum (FBS, Cat. 16140071, Thermo Fisher Scientific), 0.1% penicillin/streptomycin (Cat. 10378016, Thermo Fisher Scientific), 20 ng/ml EGF (Cat. PHG0311, Thermo Fisher Scientific), 40 μg/ml Fungizone (Cat. 15290026, Thermo Fisher Scientific), and 2% B27 supplement (Cat. 17504-044, Thermo Fisher Scientific), and the growth medium was changed every 5 days. Epidermal and dermal cells used were previously frozen cells at passage 1, and after thawing, the cells were cultured for two more passages (passage 3) to obtain sufficient numbers of cells for all experiments. These dermal and epidermal progenitor cells have been proven to be multipotent after culture expansion [22, 25].

Construction of bilayer TESSs

Bilayer TESSs are composed of a stratified epithelial layer containing differentiated epidermal cells on the top of a dermal layer containing differentiated dermal fibroblasts mixed with collagen matrix and was constructed according to a previously described protocol [26]. A schematic of the production of TESSs is shown in Additional file 1: Figure S1a-f.

(1) First, an acellular collagen layer is established that acts as an attachment substrate for the cellular layer (Additional file 1: Figure S1a) and prevents the cellular collagen from contracting from the insert membrane and detaching from it. Preparing the acellular collagen mixture on ice prevents premature gelation: mix 0.57 ml 10× MEM (Cat. 61100087, Thermo Fisher Scientific), 3.4 ml 2.5 mg/ml bovine type I collagen (Cat. 804592, Sigma-Aldrich), 0.83 ml FBS, 55 μl 200 mM L-glutamine (Cat. G7513, Sigma-Aldrich), and 2.0 ml DMEM, then adjust the pH to 7.2 with saturated NaHCO3 (Cat. S5761, Sigma-Aldrich). Use chilled pipets and avoid creating air bubbles when mixing. Add 1 ml of that mixture to each well of 6-well tissue culture plate transwells, ensuring that the gel coats the entire transwell bottom. The plates are then cultured at 37 °C, 5% CO2 in an incubator, and the mixture will gel in 30 min.

(2) Second, a collagen matrix with dermal progenitor cells is constructed on top of the acellular collagen layer (Additional file 1: Figure S1b). Dermal progenitor cells are resuspended to a final concentration of 2 × 10⁵ cells/ml in DMEM. Mix 1.65 ml 10× MEM, 6.5 ml 2.5 mg/ml bovine type 1 collagen, 1.8 ml FBS, 165 μl 200 mM L-glutamine, and 2.0 ml DMEM, then adjust the pH to 7.2 with saturated NaHCO3, add 6.75 ml 2 × 10⁵ fibroblasts/ml, and mix the ingredients together thoroughly. Add 3 ml of that mixture into each insert on top of the gelled acellular collagen matrix and incubate the plates at 37°C, 5% CO2 in an incubator. When the cellular matrix is completely gelled after 60 min, add 10 ml fibroblast culture medium to each well around the insert and 2 ml directly in the insert. Incubate the matrix and allow it to contract until day 4 (Additional file 1: Figure S1c).

(3) Third, establish the epidermal cell layer (Additional file 1: Figure S1d). After contraction is complete and the matrix is stabilized at day 4, adult epidermal stem cells are added to the surface of the matrix. A total of 2 × 10⁵ keratinocytes in 100 μl DMEM per insert should be seeded directly onto the contracted collagen gels, then incubated for 60 min at 37 °C (without medium) to allow the keratinocytes to fully adhere. Epidermal cells are allowed to attach to the substrate to generate a confluent cellular monolayer that will initiate tissue stratification.

(4) Fourth, culture different stages of TESSs. Add 12 ml epidermalization medium to each insert according to a previously described protocol [26], 10 ml to the bottom and 2 ml on top. Change the medium every 2 days until day 11 (Additional file 1: Figure S1e). The tissues are then raised to the air-liquid interface at day 12 to enable complete stratification and changed to the air-liquid epidermalization medium by adding 7 ml medium to the bottom of the well and ensuring that the insert just contacts the medium every other day until day 21 (Additional file 1: Figure S1f).

TESSs were collected at four different time points during the culture for in vitro and in vivo analyses, summarized in Additional file 1: Figure S1: (1) TESS-5d—the TESS was collected at day 5 (1 day after adding epidermal stem cells, Additional file 1: Figure S1d); (2) TESS-9d—the TESS was collected at day 9 (including 4 days of epidermalization medium culture, Additional file 1: Figure S1e); (3) TESS-14d—the TESS was collected at day 14 (including 6 days of epidermalization medium culture and 3 days of air-liquid interface culture, Additional file 1: Figure S1f); and (4) TESS-21d—the TESS was collected at day 21 (including 6 days of epidermalization medium culture and 10 days of air-liquid interface culture, Additional file 1: Figure S1f). The detailed culture information for each TESS is summarized in Additional file 1: Table S1.
Grafting of TESSs in vivo
The grafting protocol for TESSs and a schematic diagram are shown in Additional file 1: Figure S2, modified from a previously published study [27–29]. Briefly, before grafting, a silicon membrane is placed over the inset and it is flipped over with the full-thickness model. Eight-week-old female athymic nude/nude mice (Cat. 403, Charles River, Beijing, China) were prepared for surgery and draped with betadine solution under anesthesia; 6 mice were used for each grafting group. An area around 2 cm², which is similar to the size of the anesthesia; 6 mice were used for each grafting group. An

Western blot analysis
Western blot analysis was done following standard protocols [33]. Briefly, TESSs were washed three times with ice-cold phosphate-buffered saline (PBS, Cat. 10010049, Thermo Fisher Scientific) and then lysed with radioimmunoprecipitation assay (RIPA, Cat. 89900, Thermo Fisher Scientific) buffer containing 1% phenylmethylsulfonyl fluoride (PMSF, Cat. 36978, Thermo Fisher Scientific) and 1% phosphatase inhibitor cocktails. Protein concentrations were determined using a bicinchoninic acid (BCA) protein quantitation kit (Cat. PC0020, Solarbio) following the manufacturer’s protocol. Twenty micrograms of each protein sample was loaded on SDS-PAGE gels then electro-transferred to polyvinylidene fluoride (PVDF) membranes (Cat. 88518, Thermo Fisher Scientific). The membranes were incubated with the specific primary antibodies overnight at 4 °C after incubation with blocking buffer (Cat. 37580, Thermo Fisher Scientific) for 1 h. The following day, the membranes were washed with TBST (Cat. T1081, Solarbio) and incubated with secondary antibodies for 4 h at room temperature. Detection was performed with chemiluminescence reagents (Cat. SW2050, Solarbio), and immunoreactive bands were quantified using ImageJ analysis. The following primary and secondary antibodies were used: rabbit anti-cleaved Caspase-3 antibody (Cat. 9664, Cell Signaling Technology), rabbit anti-Pro-Caspase-3 (Total Caspase-3) antibody (Cat. ab32499, Abcam), rabbit anti-cytokeratin 1 antibody (Cat. ab93652, Abcam), rabbit anti-cytokeratin 5 antibody (Cat. ab52635, Abcam), rabbit anti-p63 antibody (Cat. ab124762, Abcam), rabbit anti-GAPDH antibody (Cat. ab181602, Abcam), and HRP anti-rabbit (Cat. 7074, Cell Signaling Technology).

Hematoxylin and eosin, immunohistochemistry, and immunofluorescence staining
The grafted tissues were collected at the desired times and were fixed with 4% paraformaldehyde (PFA), then were embedded in paraffin blocks. Six-micrometer sections of paraffin-embedded tissues were made for H&E staining, IHC, and IF analyses following standard protocols [30–32]. The following staining kits were used according to the manufacturers’ supplied protocols: an Alcian blue-Periodic Acid Schiff (PAS) stain kit (Cat. ab245876, Abcam, Cambridge, MA, USA) that was used to stain the basement membrane and a Masson’s trichrome stain kit (Cat. G1340, Solarbio, Beijing, China) that was used to stain collagen fibers. The following primary antibodies were used: monoclonal mouse anti-human pan-cytokeratin (pan-ck, keratin 14/15/16/19, Cat. 550951, BD Biosciences, San Jose, CA, USA), monoclonal rabbit anti-Ki-67 (Cat. ab15580, Abcam), monoclonal mouse anti-human vimentin (Cat. 3390, Cell Signaling Technology, Danvers, MA, USA), polyclonal rabbit anti-keratin 10 (Cat. ab111447, Abcam), polyclonal rabbit anti-p63 antibody (Cat. ab53039, Abcam), rabbit anti-CD31 antibody (Cat. ab134168, Abcam), rabbit anti-β-catenin antibody (Cat. ab16051, Abcam), and rabbit anti-loricrin antibody (Cat. ab93652, Abcam). The following secondary antibodies were used: Alexa fluor-488 donkey anti-mouse IgG (Cat. ab150105, Abcam), Alexa fluor-594 donkey anti-mouse IgG (Cat. ab150108, Abcam), Alexa fluor-594 donkey anti-rabbit IgG (Cat. ab150076, Abcam), and goat anti-rabbit IgG H&L (Cat. ab205718, Abcam). Dilutions of 1:400 were used for all secondary antibodies. The stained slides were mounted with a mounting medium containing DAPI to stain the nuclei (Cat. ab104139, Abcam).

qRT-PCR analysis
Total RNA was extracted from cells using a QIAGEN RNeasy Plus Mini Kit (QIAGEN, Germantown, MD, USA) according to the manufacturer’s instructions. The RNAs were dissolved in nuclease-free water, and their concentrations were measured using a Nanodrop spectrophotometer. qRT-PCR was carried out in 12.5 μl reaction volumes using a KAPA SYBR FAST One-Step Universal Kit (KAPA Biosystems, Woburn, MA, USA) with an ABI 7500 Fast System programmed as follows: 42 °C for 5 min, 95 °C for 1 min, and 40 cycles of PCR at 95 °C for 15 s, and 60 °C for 30 s. Data were acquired and analyzed with t 7500 Fast System SDS software. The human ribosomal gene 36B4 was used as a housekeeping
Statistical analysis
For all quantification data, Student’s t test analysis was used when comparing an experimental group with a control group, and one-way or two-way ANOVA with correction for multiple pairwise comparisons was used when comparing more than two groups with one or two independent variables, respectively [34, 35]. All experiments were repeated with at least three technical replicates in each experiment, and typical representative experiments are shown in all cases. Error bars reported indicate standard errors of the means (SEMs), and p values < 0.05 are considered significant and are indicated in the figures with asterisks. Comparisons not marked were not significantly different.

Results
Better efficiency of grafting after transplantation of early-stage TESS
To test whether different stages of TESSs affect the efficiency of grafting in vivo after transplantation, reconstituted TESSs from skin progenitor cells were collected at four time points: from early-stage (day 5 (TESS-5d) and day 9 (TESS-9d)) and from late-stage (day 14 (TESS-14d) and day 21 (TESS-21d)). Before the transplantation, the histology of those TESSs was assessed by H&E staining (Fig. 1a). H&E staining showed that TESS-5d only formed a thin monolayer of the epidermis, and with increased culture time, the epidermis became thicker and contained multiple layers of differentiated keratinocytes. The all-over thickness of the dermis was comparable in all 4 groups, but the dermis became denser with more matrix deposition in late-stage TESSs compared to TESS-5d.

TESSs with the same size (around 2 cm², formed in 6-well plates) from each group were grafted on the dorsal skin of female athymic nude/nude mice. Four weeks after the transplantation, the successful surviving grafts were clearly visualized by pigmented areas (dashed lines, Fig. 1b) since the host skin of athymic nude/nude mice showed no pigmentation. To further confirm those histological results, the differentiation status of the formed epidermis was assessed by IF staining of β-catenin, a component of adherens junctions. Keratinocytes were well connected with each other in the epidermis, and there was no significant difference in β-catenin staining patterns among the 4 groups at 4 weeks (Fig. 2c).

In order to further confirm those histological results, the differentiation status of the formed epidermis at 4 weeks after transplantation was assessed by IF staining of different epidermal differentiation markers. First, pan-ck, an antibody that specifically binds to the human basal cell markers cytokeratins 14, 15, 16, and 19, was positive in the basal layer of the formed epidermis in all 4 groups (Fig. 2d) and also confirmed that the epidermal cells are of human origin. The suprabasal cell marker keratin 10 (K10) was localized in the suprabasal layer of the epidermis and was not present in the basal cell layer (Fig. 2e). Loricrin, a component of the stratum corneum, was localized at the top of the epidermis (Fig. 2f). These results show that the epidermis in the graft area had a normal architecture structure with a normal differentiation status.

Normal differentiated epidermis is formed from the transplantation of different stages of TESSs
To further characterize the structure of grafted skins formed from different stages of TESSs, we evaluated the histological structure of the epidermis formed at 4 and 8 weeks after transplantation. H&E staining showed that the formed epidermis (stratified epithelia) of all four groups contained multiple layers of keratinocytes, which were composed of two distinct layers according to their morphology: a polarized basal cell layer and a suprabasal layer containing spinous, granular, and cornified layers (Fig. 2a, b). Histological analysis showed no significant differences in epidermal architecture between 4 and 8 weeks for all TESSs, indicating that a normal and stratified epidermal structure was already formed at 4 weeks after grafting. Next, we examined the cell-cell organization in the formed epidermis using IF staining of β-catenin, a component of adherens junctions. Keratinocytes were well connected with each other in the epidermis, and there was no significant difference in β-catenin staining patterns among the 4 groups at 4 weeks (Fig. 2c).
Taken together, these results suggested that early-stage TESSs with a thin layer of the epidermis (TESS-5d, Fig. 1a) produced a normally differentiated and stratified epidermis within 4 weeks after transplantation, and the overall thickness of the epidermis was equal to, or in some cases, even slightly thicker, than that formed from the transplantation of late-stage TESSs.

**Increased Ki-67 and p63 expression in the epidermis formed from early-stage TESSs**

Early-stage TESS containing a monolayer epidermis developed into mature stratified epithelia similar to that formed from later-stage TESSs at 4 weeks after transplantation in vivo. We speculated that the epidermal cells might proliferate more rapidly in the epidermis formed from TESS-5d after transplantation. IHC staining of the proliferation marker Ki-67 for grafts at 4 and 8 weeks after transplantation (Fig. 3a, b) revealed that proliferating cells were mainly located in the basal layer of the epidermis in all groups as expected. Then, we performed IF staining of human pan-ck (red, d) and human vimentin (green, e) in the pigmented area from b. DAPI stains the nuclei (blue). The white dashed line indicates the boundary between the human skin graft and the host mouse skin (bars = 50 μm). f, g The average size of pigmented skin areas at 4 and 8 weeks after transplantation. *p < 0.05, **p < 0.01 when two groups were compared as indicated; none of the other comparisons was significantly different (3 mice for each group, n = 3)

Fig. 1 TESSs from different time points produce pigmented skin after grafting. a Representative H&E-stained images of TESSs at different time points (bars = 50 μm). b Representative images of the skin in graft areas at 4 weeks after transplantation of different TESSs (bars = 5 mm). The white dashed line indicates the border of the host mouse skin and the pigmented human graft skin area. c Representative image of H&E staining of the pigmented area from b. The black dashed line indicates the boundary between the human skin graft area and the host mouse skin. d, e IF staining of human pan-ck (red, d) and human vimentin (green, e) in the pigmented area from b. DAPI stains the nuclei (blue). The white dashed line indicates the boundary between the host mouse skin and the pigmented human skin graft area (bars = 50 μm). f, g The average size of pigmented skin areas at 4 and 8 weeks after transplantation. *p < 0.05, **p < 0.01 when two groups were compared as indicated; none of the other comparisons was significantly different (3 mice for each group, n = 3).
layer among all groups (Fig. 3c, d). Quantification of the percentage of stained cells showed there were more Ki-67-positive proliferating cells in the epidermis formed from transplants of early-stage TESSs (TESS-5d or TESS-9d) compared to late-stage TESSs (TESS-14d or TESS-21d) (Fig. 3e, f). For quantification of p63-positive cells, overall, the number of p63-positive cells in the epidermis of early-stage TESSs (TESS-5d or TESS-9d) was higher than that of late-stage TESSs, especially higher than TESS-21d, although there was no significant difference between TESS-9d and TESS-14d, and there was no statistically significant difference between TESS-5d and TESS-9d as well (Fig. 3g, h). Taken together, these data suggested that epidermal cells from early-stage TESSs have more potential to proliferate and differentiate after transplantation.

Thicker dermis appears in the skin formed from transplants of early-stage TESSs

Next, we characterized the dermis formed from transplants of different stages of TESSs. H&E staining showed that the overall structure of the dermis was not significantly different among all groups at 4 and 8 weeks after grafting (Fig. 4a–d). The thickness of the dermis was measured as indicated in Fig. 4a, c, and the average thickness is shown in Fig. 4b, d. Interestingly, these data showed that the dermis formed from early-stage TESSs was slightly thicker than the dermis formed from late-stage TESSs, and especially, TESS-21d produced the thinnest dermis compared to the other groups. Next, we examined the density of dermal cells in the formed dermis. H&E staining showed that there were more cells in the dermis formed from early-stage TESSs (Fig. 4a, b). To confirm that observation, we performed IF staining using an
antibody to human vimentin, a mesenchymal cell marker, and confirmed that the dermal cells were of human origin (Fig. 4e, g). Quantification of vimentin-positive cells in the formed dermis revealed that there were more vimentin-positive cells in the dermis from early-stage TESSs than in late-stage TESSs (Fig. 4f, h). To further evaluate the distribution of dermal fibroblasts, Masson’s trichrome staining was carried out to analyze the organization of collagen

Fig. 3 The epidermis from early-stage TESSs contains more Ki-67- and p63-positive cells. a, b Representative images of Ki-67 IHC staining of the epidermis formed 4 (a) and 8 (b) weeks after grafting different stages of TESSs. c, d Representative images of IF staining (red) of p63 in the epidermis formed 4 (c) and 8 (d) weeks after grafting different stages of TESSs; DAPI stains the nuclei (blue). e, f Quantification of the percentage of Ki-67-positive cells in the basal cell layer by counting the number of Ki-67-positive cells in a total of 200 basal cells with DAPI staining from a for 4 and b for 8 weeks after transplantation. g, h Quantification of the percentage of p63-positive cells in the epidermis formed by counting the number of p63-positive cells in a total of 200 epidermal cells with DAPI staining from c for 4 and d for 8 weeks after transplantation. *p < 0.05, **p < 0.01, ***p < 0.005 when two groups were compared as indicated; none of the other comparisons was significantly different (3 mice for each group, n = 3); bars = 50 μm
fibers (blue stain) in the dermis. The distribution and structure of collagen fibers and bundles (stained blue) were comparable in TESSs of all groups, and the collagen fibers were organized and aligned in bundles in all groups, but collagen fibers of late-stage TESSs were slightly denser (Fig. 4i, j). Taken together, these results suggest that the structure of the dermis formed from the transplantation of early-stage TESSs is comparable to the dermis formed from late-stage TESSs, but early-stage TESSs produced a thicker dermis with more dermal cells after transplantation.

An intact basement membrane is formed with more CD31-positive cells in the dermis of early-stage TESSs.

The integrity of the skin structure requires an intact basement membrane which adheres the epidermis and
Hair follicle formation is only observed in the skin formed from early-stage TESSs

Currently, one of the main problems for treatment with TESSs is the lack of skin appendages such as hair follicles. Interestingly, some hair follicle formation was observed in grafts from early-stage TESSs at 8 weeks after transplantation by histological analysis (Fig. 5g). The hair follicles contained a dermal papilla (blue arrow) and were associated with sebaceous glands (green arrow), and Ki-67 staining demonstrated an active hair matrix with high numbers of proliferating cells (brown arrows, Fig. 5h). Staining with the antibody to human pan-ck confirmed that the hair follicle epidermal cells formed were derived from human cells (Fig. 5i), and the human origin of mesenchymal cells surrounding the hair follicles, stained with p63, was also verified (Fig. 5j). Staining of K10 was localized in the epithelial sheath as a typical epidermal differentiation marker (Fig. 5k). By analysis of all 6 grafts to quantify hair follicle formation, we found that 4 out of a total of 6 grafts (around 65%) formed hair follicles in the transplants of TESS-5d, and 1 of 6 grafts (16%) in the transplants of TESS-9d, but no hair follicle formation was found in the transplants of TESS-14d or TESS-21d. Taken together, these results suggested that cells in early-stage TESSs, especially TESS-5d, have a greater potential to develop into hair follicles compared with late-stage TESSs.

Early-stage TESSs express high levels of p63 and have less activation of the apoptotic pathway before transplantation

In order to understand the potential underlying mechanism of early-stage TESSs to produce a better structure of skin after transplantation, TESSs at 5, 9, 14, and 21 days were collected before grafting for western blot analysis of their expression of various differentiation markers, p63, and markers of cell apoptosis (Fig. 6a). The expression of the basal cell marker keratin 5 (K5) was not different among the 4 groups, but the expression of the suprabasal marker keratin 1 (K1) was significantly enhanced with increased culture time in vitro. Importantly, TESS-5d expressed a much higher level of p63, which is crucial for the initiation of epithelial stratification and the maintenance of basal keratinocyte proliferation, compared with the other groups. The expression of p63 was downregulated with increased culture time in vitro (Fig. 6a, b), which was consistent with the in vivo results of p63 staining (Fig. 3c, g). Finally, the expression of cleaved Caspase-3 (C-Caspase-3) was increased with a longer culture time, indicating the activation of cellular apoptosis during the in vitro culture (Fig. 6a), while the activated form of Pro-Caspase-3 (Total Caspase-3) was significantly increased, and the level of Pro-Caspase-3 was reduced correspondingly (Fig. 6a, b). This was further confirmed by qRT-PCR analysis of the expression of the apoptotic markers p21 and Bax, whose expression was increased in late-stage TESSs, and the expression of Bcl-2, an anti-apoptotic gene, was decreased in late-stage TESSs (Fig. 6c). These results suggested that early-stage TESSs contain more undifferentiated cells with higher expression levels of p63 and fewer apoptotic cells compared to late-stage TESSs.

Discussion

Our study demonstrates that early-stage bilayer TESSs with short-term culture produce a better structure of skin after transplantation in vivo, which potentially benefits better healing for the treatment of wounds. Skin tissue engineering studies started 3 decades ago [36, 37], and autologous epidermal sheets were the first TESSs to be used clinically for the successful treatment of skin burns and played life-saving roles in the 1980s [5]. More recently, using that approach, autologous genetically modified TESSs after transplantation successfully replaced mutant cells to cure epidermolysis bullosa, a genetic skin disorder characterized by the easy formation of blisters [38]. Therefore, TESSs have provided a prospective source of advanced therapies not only for the treatment of acute and chronic skin wounds, but also for genetic skin disorders [7, 8]. So far, based on different demands, different kinds of TESSs have been developed that can be categorized into three groups: epithelial, dermal, and epidermal/dermal (bilayer) replacement materials associated with either analogous or autologous cells [9]. Autologous bilayers (epidermal/dermal layers) of TESSs have been highly recommended for clinical applications because they not only contain full-thickness skin...
but also can form permanent engraftments after transplantation without immune rejection [7, 39, 40]. However, there are several limitations, including the lack of skin appendages and the time requirements, for autologous bilayer TESSs to be widely used in the clinic [6, 11, 14, 15].

The application of stem cells, which are cells with high potential to proliferate and differentiate, has been proven...
to play essential roles in the regeneration of skin structures both in vitro skin models and in vivo wound healing [38, 41], and more recently, an entire hair-bearing human skin was generated in organoids using embryonic stem cells [42]. Therefore, skin progenitor cells, including scalp-derived dermal progenitor cells and epidermal stem cells, which were prepared in our laboratory and have already been shown to possess the capacity to generate full-thickness skin containing skin appendages, including hair follicles and sebaceous glands [15, 22, 29, 31], were used to reconstitute bilayer TESSs in the present study. TESSs collected at early-stage (day 5 and day 9) and at late-stage (day 14 and day 21) were grafted on full-thickness wound areas of mouse dorsal skin to cover the wounds. Four weeks after grafting, all reconstituted skins formed from transplants of different stages of TESSs had smoothly integrated with the host mouse skin (Fig. 1b–e), and completely covered the wound area (Fig. 1b). All skins formed contained a stratified pigmented epidermis with a normal differentiated structure, which is important for the barrier function, a normal extracellular matrix (ECM) deposited on the dermis and an intact basement membrane between them, which is essential for the integrity of the skin formed (Figs. 1, 2, 4, and 5). These results demonstrate that early-stage TESSs, with as little as 5 days of culture (TESS-5d), are able to produce a comparable structure of the skin as is formed by late-stage mature TESSs (TESS-14d and TESS-21d) at 4 weeks after transplantation.

Surprisingly, further analysis revealed that several features of the skin formed from early-stage TESSs were better than those formed from late-stage TESSs: (1) The size of grafts taken in the group of transplanted early-stage TESSs was larger than those of late-stage TESSs (Fig. 1b, f, g), which suggests that the shrinkage or contracture of early-stage TESSs after grafting was likely less than that of late-stage TESSs. The contracture of skin grafts is a crucial factor that affects the efficacy of wound healing; therefore, it is important to minimize the contracture or shrinkage of grafts which will benefit wound care [43, 44]. (2) The thickness of the dermis formed from early-stage TESSs was greater than that formed from late-stage TESSs (Fig. 4a–d). The density of dermal fibroblasts, the main cell component of the dermis...
recognized by the vimentin antibody, was higher in the dermis formed from early-stage TESSs (Fig. 4e–h). There were no significant differences in the density of collagen fibers, the main structural element of the ECM, produced by dermal fibroblasts, among all groups, although we observed slightly denser collagen fibers in the dermis formed from the late-stage TESS-21d (Fig. 4i, j). This could be due to some collagen fibers already produced in the TESS-21d during in vitro culture before grafting, since previous studies showed significant collagen deposition in cultures of late-stage TESSs [45, 46]. Concerning the important role of the dermis in skin regeneration, the reconstitution of a better structure of the dermis will significantly improve the quantity of skin wound healing and will reduce scar formation [47]. (3) The number of microvessels in the dermis formed from early-stage TESSs was more than those formed from late-stage TESSs (Fig. 5c–f). Insufficient vascularization is a major threat to the clinical use of TESSs, as it can cause the TESSs to loosen, become susceptible to infection, or experience partial necrosis [48]. The greater vascularization in early-stage TESSs definitely could enhance the efficiency of grafts taken (Fig. 1b, f, g). (4) Notably, the mature hair formation associated with the sebaceous glands were only observed in grafts from early-stage TESSs (Fig. 5g–k). The formation of skin appendages such as hair follicles and sebaceous glands from grafts of TESSs provides a potential opportunity to reconstitute a fully functional skin, which is the ultimate goal for repairing wounds using TESSs. Based on these findings, we conclude that early-stage TESSs produce a better skin structure after transplantation in vivo compared to late-stage TESSs. In addition, the overall structure of the skin formed from TESS-5d was comparable to that formed from TESS-9d; however, the efficiency of hair follicle formation was significantly higher in the TESS-5d, suggesting that the TESS-5d is better than TESS-9d to potentially produce a functional skin.

Our findings indicate that early-stage TESSs likely consist of high potential cells, which possess a high capacity to proliferate and differentiate after transplantation in vivo. Indeed, Ki-67 staining revealed that there were more proliferating epidermal cells in grafts of early-stage TESSs (Fig. 3a, b, e, f), which also could explain how early-stage TESSs with a monolayer of the epidermis at 4 weeks after transplantation could produce a similar thickness of the epidermis as grafts of late-stage TESSs. The strong staining of the epidermal progenitor cell marker p63 (Fig. 3c, d, g, h), which is essential for the proliferation, stratification, and differentiation of skin epidermal cells [49, 50], and the higher expression level of p63 in early-stage TESSs was also verified by in vitro analysis (Fig. 6), which suggested that cells in early-stage TESSs have more potential than cells in late-stage TESSs. A previous study by Larouche et al. reported that hair formation was observed when grafting TESSs formed from newborn mouse hair buds together with mouse dermal cells; however, the number of normal hair follicles was significantly decreased with longer culture time [51]. Taken together, these results suggest that with a longer culture time, there are fewer trichogenic cells in TESSs that fail to reconstitute skin appendages. Moreover, in vitro analysis of the expression of genes involved in apoptosis pathways, including the anti-apoptotic protein Bcl-2 [52] and the proapoptotic proteins p21 and Bax [53–55], in different stages of TESSs, revealed a higher expression of Bcl-2, but a lower expression of p21 and Bax in early-stage TESSs compared with late-stage TESSs (Fig. 6). These results indicate an increased activation of apoptosis with increased culture time, which was confirmed by analysis of cleaved Caspase-3, a key factor in apoptosis execution [56]. These data again support the benefit of transplanting early-stage TESSs for the treatment of wounds.

Currently, late-stage mature bilayer TESSs, which usually require at least 1 week of culture after lifting to the air-liquid interface to mature (see Additional file: Figure S1), have been mainly used for grafting in vivo (both for animal models and for clinical use) [57]. To our knowledge, little research has been done to study whether early-stage TESSs with minimal development of the epidermal layer, which require much less culture time, could form a normal skin structure in vivo after transplantation. Shortening the preparation time of TESSs will not only meet the requirements of clinical application in a timely manner, but will also reduce the cost of producing TESSs. The present study is the first to demonstrate that early-stage TESSs can form hair-bearing skin after transplantation in vivo, which provides an opportunity to deliver autologous TESSs for clinical application up to 2 weeks earlier than the current procedure for the treatment of wounds.

The ultimate goal of tissue engineering skin is to rapidly produce a construct that offers the complete regeneration of functional skin, including all layers (epidermis, dermis, and subcutaneous tissue), all skin appendages (hair follicles, sweat glands, and sensory organs), and a functional vascular and nerve network [6, 58]. Our system still has a lot of room to develop further to reach the above goals since we have not observed any formation of sweat glands or a fat layer in our grafts so far. Therefore, our future work will focus on optimizing our system by applying modern medical technologies such as three dimensional (3D) bioprinting and/or adding different stem cell sources such as adipose-derived mesenchymal stem cells or growth factors, which would promote the
regeneration of skin appendages, to quickly and efficiently reconstitute advanced TESSs with the potential to form fully functional skin in vivo after transplantation.

**Conclusions**
In summary, the present study demonstrates that early-stage bilayer TESSs, reconstituted from adult skin progenitor cells, contain more competent cells with less activation of the apoptotic pathway and produce a better structure of the skin including hair follicle formation after transplantation compared to late-stage TESSs. These results suggest that the development of early-stage TESSs, which require much less culture time, potentially provides a better healing for the treatment of wounds and promotes its application in the clinic in the future.

**Supplementary information**

**Supplementary information** accompanies this paper at https://doi.org/10.1186/s13287-020-01924-z.

**Abbreviations**
3D: Three dimensional; BCA: Bicinchoninic acid; C-Caspase-3: Cleaved Caspase-3; ECM: Extracellular matrix; FBS: Fetal bovine serum; H&E: Hematoxylin and eosin; IF: Immunofluorescence; iHSC: Immunohistochemistry; iPSCs: Induced pluripotent stem cells; K1: Keratin 1; K10: Keratin 10; KS: Keratin 5; pan-ck: Pan-cytokeratin; PAS: Periodic acid Schiff; PBS: Phosphate-buffered saline; PFA: Paraformaldehyde; PMSF: Phenylmethylsulfonyl fluoride; PVDF: Polyvinylidene fluoride; RIPA: Radio immunoprecipitation assay; SEMs: Standard errors of the means; TESS: Tissue-engineered skin substitute

**Acknowledgements**
We gratefully acknowledge the members of the Wu Lab for the helpful discussions and technical assistance.

**Authors’ contributions**
QZ and XW designed the experiments. QZ, JW, CL, CM, FB, XL, ZC, ZX, and JM conducted the experiments. QZ and XW analyzed the data and wrote the manuscript. All authors approved the submitted version of the manuscript.

**Funding**
This work was supported by The National Key Research and Development Program of China (2017YFA0104604), the General Program of National Natural Science Foundation of China (81772093), the Key Program of Shandong Province Natural Science Foundation (ZR2017ZD06), the Key Research and Development Program of Shandong Province (2019GSF108107), and the Military Logistics Research Project (AWS171005) to X.W., and by the Medical and Health Science and Technology Development Project of Shandong Province (2018WS163) to Z.X.

**Availability of data and materials**
The dataset used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

**Ethics approval and consent to participate**
All human tissues were collected from discarded hospital specimens without any personal identity information after receiving the protocol approval by the Medical Ethical Committee of the School of Stomatology, Shandong University (NO.2015120401, date: 05 December 2015). The animal protocol in this study was approved by the ethics committee of the Hospital of Stomatology, Shandong University (NO.2015120402, Date: 05 December 2015), and all of the animal procedures were carried out in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and the principles of the Basel Declaration.

**Consent for publication**
Not applicable

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1 Department of Tissue Engineering and Regeneration, School and Hospital of Stomatology, Cheooloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, No.44-1 Weihua Road West, Jinan, Shandong, China. 2 Shandong Provincial Key Laboratory of Animal Cells and Developmental Biology, School of Life Science, Shandong University, Qingdao, China. 3 Oulu Children’s Hospital of Shandong University, Jinan, China. 4 Department of Stomatology, Shengli Oilfield Center Hospital, Dongying, Shandong, China.

Received: 15 June 2020 Revised: 27 July 2020 Accepted: 3 September 2020

**References**
1. Pirnay JP, Vanderkelen A, Dos V, Draye JP, Rose T, Ceulemans C, et al. Business oriented EU human cell and tissue product legislation will adversely impact Member States’ health care systems. Cell Tissue Bank. 2013;14:525–60.
2. Sun BK, Sipasrivi V, Khavari PA. Advances in skin grafting and treatment of cutaneous wounds. Science. 2014;346:941–5.
3. Henndon DN, Barrow RE, Rutan RL, Rutan TC, Desai MH, Abston S. A comparison of conservative versus early excision. Ann Surg. 1989;209:547–53.
4. Peppas N, Langer R. New challenges in biomaterials. Science. 1994;263:1715–20.
5. Gallico GG, O’Connor NE, Compton CC, Kehinde O, Green H. Permanent coverage of large burn wounds with autologous cultured human epithelium. N Engl J Med. 1984;311:448–51.
6. Vign K, Chaudhari A, Tripathi S, Dixit S, Sahu R, Pillai S, et al. Advances in skin regeneration using tissue engineering. Int J Mol Sci. 2017;18:789.
7. Royce ST, Lalley AL. Tissue engineering of skin and regenerative medicine for wound care. Burns Trauma. 2018;6:4.
8. Chua AW, Khoo YC, Tan SK, Tan KC, Foo CL, Chong SJ. Skin tissue engineering advances in severe burns: review and therapeutic applications. Burns Trauma. 2016;4:3.
9. MacNeil S. Progress and opportunities for tissue-engineered skin. Nature. 2007;445:874–80.
10. Beldon P. Skin grafts 1: theory, procedure and management of graft sites in the community. Br J Community Nurs. 2003;8:18–19.
11. Zhang X, Yang J, Li Y, Liu S, Long K, Zhao Q, et al. Functional neovascularization in tissue engineering with porcine acellular dermal matrix and human umbilical vein endothelial cells. Tissue Eng Part C Methods. 2011;17:423.
12. Blais M, Parenteau-Bareil R, Cadau S, Berthod F. Concise review: tissue-engineered skin and nerve regeneration in burn treatment. Stem Cells Transl Med. 2013;2:545–51.
13. Monfort A, Navarro MS, Verdugo JMG, Izeta A. Production of human tissue-engineered skin containing melanocytes. Cell Bio Int. 2013;37:1985–90.
14. Liu F, Luo XS, Shen HY, Dong JS, Yang J. Using human hair follicle-derived keratinocytes and melanocytes for constructing pigmented tissue-engineered skin. Skin Res Technol. 2011;17:373–9.
15. Higgins CA, Chen JC, Cerise JE, Jahoda CAB, Christiano AM. Microenvironmental reprogramming by three-dimensional culture enables...
dermal papilla cells to induce de novo human hair-follicle growth. Proc Natl Acad Sci U S A. 2013;110:19679–88.
17. Chan CC, Fan SMY, Wang WH, Mu YF, Lin SJ. A two-stepped culture method for efficient production of trichogenic keratocytes. Tissue Eng Part C Methods. 2015;21:11070–9.
18. Huang CF, Chang YJ, Hsueh YY, Huang CW, Wang DH, Huang TC, et al. Assembling composite dermal papilla spheres with adipose-derived stem cells to enhance hair follicle induction. Sci Rep. 2016;6:26436.
19. Bilic J, Belmonte JC. Concise review: induced pluripotent stem cells versus embryonic stem cells: close enough or yet too far apart? Stem Cells. 2012; 3033–41.
20. Cong L, Rani FA, Cox D, Lin S, Barreto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:1813–21.
21. Hua Q, Xue L, Jie W, Qian Z, Kunwei W. One-step simple isolation method to obtain both dermal and dermal stem cells from human skin specimen. Methods Mol Biol. 1879;2018:139–48.
22. Wen J, ZHOU T, Qiao L, Zhou G, Wu X, Xu Y. Y-27632 simplifies the isolation procedure of human primary epidermal cells by selectively blocking focal adhesion of dermal cells. J Tissue Eng Regen Med. 2017;12:251–5.
23. Zhang Q, Zu T, Zhou Q, Wen J, Leng X, Wu X. The patch assay reconstitutes mature hair follicles by culture-expanded human cells. Regen Med. 2017;12:503–11.
24. Liu Z, Wen J, Leng X, Zhou Q, Zhou C, Zhao H, et al. A simplified and efficient method to isolate primary human keratocytes from adult skin tissue. J Vis Exp. 2018;1385:7784.
25. Su Y, Wen J, Zhu J, Xie Z, Liu C, Ma C, et al. Pre-aggregation of scalp progenitor dermal and epidermal stem cells activates the WNT pathway and promotes hair follicle formation in vitro and in vivo systems. Stem Cell Res Ther. 2019;10:403.
26. Carlson MW, Alt-Holland A, Egles C, Gallick JA. Three-dimensional tissue models of normal and diseased skin. Curr Protoc Cell Biol. 2008;Chapter 19: Unit 19.9.
27. Lee LF, Jiang TX, Garner W, Chao CM. A simplified procedure to reconstitute hair-producing skin. Tissue Eng Part C Methods. 2010;17:391–400.
28. Wu X, Scott LR, Washenik K, Stenn K. Full-thickness skin with mature hair follicles generated from tissue culture expanded human cells. Tissue Eng Part A. 2014;20:3114–21.
29. MIJ, Chen S, Xu L, Wen J, Xu X, Wu W. Human reconstructed skin in a mouse model. Methods Mol Biol. 1993;1992:227–37.
30. Chang F, Zhang Y, MIJ, Zhou Q, Bai F, Xu X, et al. ROCK inhibitor enhances the growth and migration of BRAF-mutant skin melanoma cells. Cancer Sci. 2018;109:3428–37.
31. Wu X, Alice TDV, Qian Z, Michel-Dziunycz PJ, Bai F, MI J, et al. The ARE-binding protein tristetraprolin (TTP) is a novel target and mediator of calcineurin tumor suppressing function in the skin. PLoS Genet. 2018;14:e1007936.
32. Xue L, Peng W, Zhibong C, Li D, Wen J, Zhang X, et al. Dissociated skin cells regenerate hair follicles in a microwound, “The Punch Assay”. Exp Dermatol. 2018;29:349–56.
33. Zhang X, Qin J, Xie Z, Liu C, Su Y, Chen Z, et al. Y-27632 preserves epidermal integrity in a human skin organ cultura (hSOCO) system by regulating AKT and ERK signaling pathways. J Dermatol Sci. 2019;96:69–109.
34. Wahida IF, Aminuddin BS, Mazlyzam AL, Saim L, Ruszymah B, editors. Gene engineering using CRISPR/Cas systems. Science. 2013;339:1813–21.
35. Fu YF, Fan TJ. Bcl-2 family proteins and apoptosis. Acta Bioch Bioph Sin. 2002;34:389–94.
36. Milosevic J, Hoffarth S, Huber C, Schuler M. The DNA damage-induced decrease of Bcl-2 is secondary to the activation of apoptotic effector caspases. Oncogene. 2003;22:6852–6.
37. Xian LC, Jun FT, Bin HG, Shan CR. Apoptosis-inducing factor and apoptosis. Acta Bioch Bioph Sin. 2003;35:881–6.
38. Nicholson WD. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 1999;6:1028–42.
39. Priya SG, Jungvild H, Kumar A. Skin tissue engineering: wound healing based on stem-cell-based therapeutic strategies. Cell Mol Life Sci. 2018;75:1179–90.
40. Egero Guerero JJ, Carmona G, Correa E, Mata R, Arias Santiago S, Alamons M, et al. Transplant of tissue-engineered artificial autologous human skin in Andalusia: an example of coordination and institutional collaboration. Transplant Proc. 2019;51:3047–50.
41. Demkordi AN, Babayehdari FM, Chehelgerdli M, Dehkordi SR. Skin tissue engineering: wound healing based on stem-cell-based therapeutic strategies. Stem Cell Res Ther. 2019;10:1111.
42. Lee J, Rabbani CC, Gao H, Steinhardt MR, Woodruff BM, Pflumm ZE, et al. Hair-bearing human skin generated entirely from pluripotent stem cells. Nature. 2020;582:399–404.
43. Hur GF, Seo DK, Lee JW. Contracture of skin graft in human burns: effect of artificial dermis. Burns. 2014;40:1497–503.
44. Braza ME, Fahrenkopf MP. Split-thickness skin grafts. In: StatPearls. Treasure Island: StatPearls Publishing; 2020.
45. Lavoie A, Sugere C, Beauapart A, Goyer B, Larouche D, Paquet C, et al. Human epidermal stem cells persist within tissue-engineered skin produced by the self-assembly approach. Tissue Eng Part A. 2013;19:1023–38.
46. Aukenfils C, Fradette J, Lequeux C, Germain L, Kinkiloglu B, Bechetolle N, et al. Evolution of these dimensional skin equivalent models reconstructed in vitro by tissue engineering. Eur J Dermatol. 2009;19:107–13.
47. Zhou H, You C, Wang X, Jin R, Wu P, Li Q, et al. The progress and challenges for dermal regeneration in tissue engineering. J Biomed Mater Res A. 2017;105:1208–18.
48. Hendrick B, Wanckl JJ, Lutten A. Cell-based vascularization strategies for skin tissue engineering. Tissue Eng Part B Rev. 2011;17:13–24.
49. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 2004;18:126–31.
50. Soares E, Zhou H. Master regulatory role of p63 in epithelial development and disease. Cell Mol Life Sci. 2018;75:1179–90.
51. Larouche D, Cuffley K, Paquet C, Germain L. Tissue-engineered skin preserving the potential of epithelial cells to differentiate into hair after grafting. Tissue Eng Part A. 2011;17:819–30.
52. Gross A, Mcdonnell JM, Korsmeyer JS. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899–911.
53. Fu YF, Fan TJ. Bcl-2 family proteins and apoptosis. Acta Bioch Bioph Sin. 2002;34:389–94.
54. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. p63 is the molecular switch for epithelial stratification. Genes Dev. 2004;18:126–31.
55. Soares E, Zhou H. Master regulatory role of p63 in epithelial development and disease. Cell Mol Life Sci. 2018;75:1179–90.
56. Gross A, Mcdonnell JM, Korsmeyer JS. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899–911.
57. Milosevic J, Hoffarth S, Huber C, Schuler M. The DNA damage-induced decrease of Bcl-2 is secondary to the activation of apoptotic effector caspases. Oncogene. 2003;22:6852–6.
58. Xian LC, Jun FT, Bin HG, Shan CR. Apoptosis-inducing factor and apoptosis. Acta Bioch Bioph Sin. 2003;35:881–6.
59. Nicholson WD. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 1999;6:1028–42.
60. Priya SG, Jungvild H, Kumar A. Skin tissue engineering for tissue repair and regeneration. Tissue Eng Part B Rev. 2008;14:105–18.
61. Weng T, Wu P, Zhang W, Zheng Y, Li Q, Jin R, et al. Regeneration of skin appendages and nerves: current status and further challenges. J Transl Med. 2020;18:53.